Literature DB >> 36267923

Frequency of Multi-Drug Resistance and Molecular Characteristics of Resistance to Colistin in Acinetobacter baumannii Collected from Patients in Intensive Care Units with Ventilator-Associated Pneumonia.

Samaneh Babaei1, Mihan Pourabdollah2, Masoumeh Aslanimehr3, Farhad Nikkhahi4, Saeid Mahmoodian2, Yasaman Hasani5, Fatemeh Maryam Sheikholeslami6.   

Abstract

Background: Acinetobacter baumannii is one of the most common causes of ventilator-associated pneumonia (VAP) in patients hospitalized in ICU. Multiple resistance has resulted in excessive use of Colistin antibiotic, which is the latest treatment option for this bacterium. Therefore, the purpose of this study was to determine the abundance of multi-resistance and molecular characteristics of resistance to colistin among A. baumannii isolated from patients that are infected with VAP and hospitalized in ICU of "Qazvin" and "Masih Daneshvari" hospitals. Materials and
Methods: In this study, 200 A. baumannii isolates related to VAP were collected from ICU of "Masih Daneshvari" (2012-2018) and "Qazvin" (2017-2018) hospitals, from bronchoalveolar lavage & tracheal aspirate specimens. Isolates were detected as A. baumannii by PCR with specific primers of the blaOXA-51-like gene. Antibacterial susceptibility of isolates to colistin was determined by the MIC method, and other antibiotics were examined by the disk diffusion method, according to the CLSI criteria. Multi-drug resistance (MDR) and extended-drug resistance (XDR) isolates were determined according to standard definitions of the CLSI.
Results: All the isolates were susceptible to colistin. Moreover, they were resistant to piperacillin, piperacillin-tazobactam, ceftazidime, cefotaxime, ceftriaxone, amikacin, gentamycin, levofloxacin, co-trimoxazole, and ciprofloxacin. Antimicrobial resistance rates for tetracycline and ampicillinsulbactam were 8.5% and 20%, respectively. All isolates were MDR and XDR. All isolates were susceptible to colistin (MIC50=1 and MIC90=2 μg/ml). The sequencing results did not show any point mutation in pmr CAB genes, and mcr-1 gene was not detected in any isolates.
Conclusion: In this study, all A. baumannii isolates collected from VAP patients were MDR and XDR. Although all isolates were susceptible to colistin, and this agent seems the most appropriate antibiotic for treatment of VAP, colistin resistance can become endemic in the world rapidly due to plasmid-mediated mobile colistin resistance mcr genes. Copyright
© 2021 National Research Institute of Tuberculosis and Lung Disease.

Entities:  

Keywords:  Acinetobacter baumannii; Colistin; MDR; XDR; mcr-1; pmr CAB

Year:  2021        PMID: 36267923      PMCID: PMC9577206     

Source DB:  PubMed          Journal:  Tanaffos        ISSN: 1735-0344


  19 in total

1.  Promoters of Colistin Resistance in Acinetobacter baumannii Infections.

Authors:  Elif Nurtop; Fulya Bayındır Bilman; Sirin Menekse; Ozlem Kurt Azap; Mehmet Gönen; Onder Ergonul; Fusun Can
Journal:  Microb Drug Resist       Date:  2019-04-09       Impact factor: 3.431

2.  A distinct alleles and genetic recombination of pmrCAB operon in species of Acinetobacter baumannii complex isolates.

Authors:  Dae Hun Kim; Kwan Soo Ko
Journal:  Diagn Microbiol Infect Dis       Date:  2015-04-09       Impact factor: 2.803

Review 3.  Colistin resistance of Acinetobacter baumannii: clinical reports, mechanisms and antimicrobial strategies.

Authors:  Yun Cai; Dong Chai; Rui Wang; Beibei Liang; Nan Bai
Journal:  J Antimicrob Chemother       Date:  2012-03-22       Impact factor: 5.790

4.  Phosphoethanolamine modification of lipid A in colistin-resistant variants of Acinetobacter baumannii mediated by the pmrAB two-component regulatory system.

Authors:  Alejandro Beceiro; Enrique Llobet; Jesús Aranda; José Antonio Bengoechea; Michel Doumith; Michael Hornsey; Hiran Dhanji; Henrik Chart; Germán Bou; David M Livermore; Neil Woodford
Journal:  Antimicrob Agents Chemother       Date:  2011-05-16       Impact factor: 5.191

5.  Molecular Mechanisms of Colistin Resistance Among Pandrug-Resistant Isolates of Acinetobacter baumannii with High Case-Fatality Rate in Intensive Care Unit Patients.

Authors:  Mehri Haeili; Mahsa Kafshdouz; Mohammad Mehdi Feizabadi
Journal:  Microb Drug Resist       Date:  2018-03-13       Impact factor: 3.431

6.  The pmrCAB operon mediates polymyxin resistance in Acinetobacter baumannii ATCC 17978 and clinical isolates through phosphoethanolamine modification of lipid A.

Authors:  Luis A Arroyo; Carmen M Herrera; Lucia Fernandez; Jessica V Hankins; M Stephen Trent; Robert E W Hancock
Journal:  Antimicrob Agents Chemother       Date:  2011-06-06       Impact factor: 5.191

7.  Colistin-resistant, lipopolysaccharide-deficient Acinetobacter baumannii responds to lipopolysaccharide loss through increased expression of genes involved in the synthesis and transport of lipoproteins, phospholipids, and poly-β-1,6-N-acetylglucosamine.

Authors:  Rebekah Henry; Nuwan Vithanage; Paul Harrison; Torsten Seemann; Scott Coutts; Jennifer H Moffatt; Roger L Nation; Jian Li; Marina Harper; Ben Adler; John D Boyce
Journal:  Antimicrob Agents Chemother       Date:  2011-10-24       Impact factor: 5.191

Review 8.  Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options.

Authors:  Lisa L Maragakis; Trish M Perl
Journal:  Clin Infect Dis       Date:  2008-04-15       Impact factor: 9.079

9.  Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens.

Authors:  Garyphallia Poulakou; Flora V Kontopidou; Elisabeth Paramythiotou; Maria Kompoti; Maria Katsiari; Efstratios Mainas; Chara Nicolaou; Dimitrios Yphantis; Anastasia Antoniadou; Eleftheria Trikka-Graphakos; Zoi Roussou; Phyllis Clouva; Nina Maguina; Kyriaki Kanellakopoulou; Apostolos Armaganidis; Helen Giamarellou
Journal:  J Infect       Date:  2009-04       Impact factor: 6.072

10.  Association of virulence gene expression with colistin-resistance in Acinetobacter baumannii: analysis of genotype, antimicrobial susceptibility, and biofilm formation.

Authors:  Abbas Bahador; Zahra Farshadzadeh; Reza Raoofian; Masoumeh Mokhtaran; Babak Pourakbari; Maryam Pourhajibagher; Farhad B Hashemi
Journal:  Ann Clin Microbiol Antimicrob       Date:  2018-06-01       Impact factor: 3.944

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.